

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

COLO 205

RRID:CVCL_0218

Type: Cell Line

Proper Citation

RRID:CVCL_0218

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0218

Proper Citation: RRID:CVCL_0218

Description: Cell line COLO 205 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:565251](#), [PMID:2041050](#), [PMID:3335022](#), [PMID:3629545](#), [PMID:6277475](#), [PMID:7651727](#), [PMID:9023415](#), [PMID:9294210](#), [PMID:9331090](#), [PMID:10051639](#), [PMID:10674020](#), [PMID:10700174](#), [PMID:10737795](#), [PMID:11414198](#), [PMID:12068308](#), [PMID:12584437](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23272949](#), [PMID:23631600](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25841592](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:25984343](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28192450](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29718670](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COLO 205

Synonyms: Colo 205, CoLo 205, COLO-205, Colo-205, COLO.205, Colo205, COLO205, Co 205, Colorado 205

Cross References: BTO:BTO_0000179, CLO:CLO_0002544, CLO:CLO_0050630, EFO:EFO_0003082, MCCL:MCC:0000107, CLDB:cl826, CLDB:cl5096, AddexBio:C0009018/4908, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CCL-222, BCRC:60054, BioGRID_ORCS_Cell_line:846, BioSample:SAMN03470991, BioSample:SAMN10987610, cancercellines:CVCL_0218, CCRID:1101HUM-PUMC000132, CCRID:3101HUMTCHu102, Cell_Model_Passport:SIDM00826, ChEMBL-Cells:ChEMBL3308348, ChEMBL-Targets:ChEMBL614561, CLS:300380, ColonAtlas:COLO205, Cosmic:685865, Cosmic:720342, Cosmic:738936, Cosmic:875901, Cosmic:876711, Cosmic:887242, Cosmic:889524, Cosmic:897456, Cosmic:902796, Cosmic:905961, Cosmic:948130, Cosmic:948823, Cosmic:974244, Cosmic:995391, Cosmic:1043806, Cosmic:1044256, Cosmic:1045404, Cosmic:1066207, Cosmic:1067224, Cosmic:1092596, Cosmic:1132577, Cosmic:1154651, Cosmic:1175838, Cosmic:1184101, Cosmic:1187303, Cosmic:1223135, Cosmic:1305351, Cosmic:1310944, Cosmic:1312336, Cosmic:1374634, Cosmic:1479612, Cosmic:1609485, Cosmic:1676745, Cosmic:1708401, Cosmic:1945864, Cosmic:1995368, Cosmic:1998438, Cosmic:2036651, Cosmic:2301968, Cosmic:2560250, Cosmic:2651868, Cosmic:2800580, Cosmic-CLP:905961, DepMap:ACH-001039, ECACC:87061208, EGA:EGAS00001000610, EGA:EGAS00001000978, FCS-free:180-2-342-3-16-3, GDSC:905961, GEO:GSM2089, GEO:GSM50186, GEO:GSM50250, GEO:GSM206459, GEO:GSM274717, GEO:GSM274718, GEO:GSM274728, GEO:GSM741249, GEO:GSM743441, GEO:GSM750794, GEO:GSM799329, GEO:GSM799392, GEO:GSM827422, GEO:GSM843490, GEO:GSM846289, GEO:GSM886940, GEO:GSM888007, GEO:GSM1153400, GEO:GSM1178029, GEO:GSM1178030, GEO:GSM1178031, GEO:GSM1181248, GEO:GSM1181264, GEO:GSM1346867, GEO:GSM1374451, GEO:GSM1374452, GEO:GSM1448172, GEO:GSM1669683, GEO:GSM2124638, GEO:GSM2549994, IARC_TP53:21116, ICLC:HTL00010, KCB:KCB 200719YJ, KCLB:10222, LINCS_LDP:LCL-1173, Lonza:253, MetaboLights:MTBLS227, NCI-DTP:COLO 205, PharmacDB:COLO205_221_2019, PRIDE:PXD001550, PRIDE:PXD003539, PRIDE:PXD005235, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0218, PubChem_Cell_line:CVCL_0218, RCB:RCB2127, SKY/M-FISH/CGH:2801, TKG:TKG 0457, Wikidata:Q54814074

ID: CVCL_0218

Record Creation Time: 20220427T215514+0000

Record Last Update: 20260905T174632+0000

Ratings and Alerts

No rating or validation information has been found for COLO 205.

No alerts have been found for COLO 205.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 231 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang W, et al. (2026) A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. *Cell reports. Medicine*, 102932.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Sritharan S, et al. (2026) Secretion of IL-6 and TGF- β 2 by Colon Cancer Cells May Promote Resistance to Chemotherapy. *Indian journal of clinical biochemistry : IJCB*, 41(2), 259.

Cong K, et al. (2026) A comprehensive review of anti-colorectal cancer alkaloids from traditional Chinese medicine: Sources, chemical structures, mechanisms and therapeutic applications. *British journal of pharmacology*.

Chen H, et al. (2026) CCL3 and IL-7 Synergistically Enhance CAR-T Efficacy in Solid Tumors. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e75993.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCR α antibody enables functional dissection of HLA-E biology and checkpoint signaling. *iScience*, 29(5), 115669.

Jothimani G, et al. (2025) Unraveling the mechanism of microRNA-134 in colon cancer progression: Targeting KRAS and PIK3CA for cell cycle control and histone deacetylase regulation. *Experimental cell research*, 444(2), 114385.

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. *Cell reports. Medicine*, 6(9), 102350.

Martinez-Martinez D, et al. (2025) Chemotherapy modulation by a cancer-associated microbiota metabolite. *Cell systems*, 16(9), 101397.

Baglamis S, et al. (2025) Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. *iScience*, 28(5), 112403.

Enciso-Martinez A, et al. (2025) Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles. *Journal of extracellular vesicles*, 14(6), e70106.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. *Cancer research*, 85(4), 758.

Ortiz-Ruiz MJ, et al. (2025) Mediator Kinase Inhibitor Selectivity and Activity in Colorectal Cancer. *ACS chemical biology*, 20(7), 1792.

Lee HM, et al. (2024) Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(22), 5166.

Eisenberg V, et al. (2024) Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells. *Cancer immunology research*, 12(10), 1380.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Xie B, et al. (2024) Strengthening E-cadherin adhesion via antibody-mediated binding stabilization. *Structure (London, England : 1993)*, 32(2), 217.

Gunji D, et al. (2024) Longitudinal phosphoproteomics reveals the PI3K-PAK1 axis as a potential target for recurrent colorectal liver metastases. *Cell reports*, 43(12), 115061.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. *Cell*, 187(11), 2703.

Wei W, et al. (2023) FBXW7 loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. *Signal transduction and targeted therapy*, 8(1), 187.